Immunome, Inc.'s (NASDAQ:IMNM) Institutional Investors Lost 6.0% Last Week but Have Benefitted From Longer-term Gains
Immunome, Inc.'s (NASDAQ:IMNM) Institutional Investors Lost 6.0% Last Week but Have Benefitted From Longer-term Gains
Key Insights
主要见解
- Institutions' substantial holdings in Immunome implies that they have significant influence over the company's share price
- 52% of the business is held by the top 11 shareholders
- Insiders have been buying lately
- 机构在Immunome拥有大量持股意味着它们对公司的股价有重大影响。
- 排名前11的股东持有该业务的52%。
- 内部人员最近一直在买入。
If you want to know who really controls Immunome, Inc. (NASDAQ:IMNM), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 52% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
如果你想知道谁真正掌控Immunome,Inc.的控股人(NASDAQ:IMNM),那么你必须看它的股东注册表。我们可以看到机构占有该公司的绝大部分股份,拥有52%的所有权。也就是说,如果股票上涨(或者出现下行),该集团将获得最大的利益。
No shareholder likes losing money on their investments, especially institutional investors who saw their holdings drop 6.0% in value last week. However, the 83% one-year returns may have helped alleviate their overall losses. They should, however, be mindful of further losses in the future.
没有股东希望自己的投资亏损,特别是机构投资者上周看到其持股市值下跌6.0%。但是,83%的一年回报率可能有助于缓解他们的整体损失。但他们应该谨防未来进一步的亏损。
Let's take a closer look to see what the different types of shareholders can tell us about Immunome.
让我们仔细看看不同类型的股东对Immunome能告诉我们什么。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240722/0-37ec2362a2b05788ffc27f1623078a59-0-3bf2e5899f56340b8f50edae31a9da0d.png/big)
What Does The Institutional Ownership Tell Us About Immunome?
机构所有权告诉我们有关Immunome什么?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
机构投资者通常将自己的回报与常见的指数回报进行比较。因此,他们通常会考虑购买包括在相关基准指数中的较大公司。
As you can see, institutional investors have a fair amount of stake in Immunome. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Immunome's earnings history below. Of course, the future is what really matters.
正如你所看到的,机构投资者在Immunome中拥有相当一部分股份。这可能表明该公司在投资社区中具有一定的信誉度。然而,最好谨慎地依赖机构投资者带来的所谓认可。他们有时也会犯错。如果多个机构同时改变对某只股票的看法,你可能会看到股价迅速下跌。因此,值得看看下面的Immunome收益历史。当然,未来才是真正重要的。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240722/0-37ec2362a2b05788ffc27f1623078a59-1-9f5f3756510b470f5a530ddedaa8b732.png/big)
Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. It would appear that 15% of Immunome shares are controlled by hedge funds. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. The company's largest shareholder is Redmile Group, LLC, with ownership of 8.2%. In comparison, the second and third largest shareholders hold about 7.6% and 6.5% of the stock. In addition, we found that Clay Siegall, the CEO has 0.7% of the shares allocated to their name.
投资者应该注意,机构实际上拥有公司的一半以上,因此可以集体行使重大权力。看起来,15%的Immunome股票由对冲基金控制。这值得注意,因为对冲基金通常是相当活跃的投资者,可能会试图影响管理层。许多投资者希望在短期或中期内看到价值创造(和更高的股价)。公司最大的股东是Redmile Group,LLC,持有8.2%的所有权。相比之下,第二大和第三大股东持有大约7.6%和6.5%的股份。此外,我们发现首席执行官Clay Siegall拥有0.7%的股份。
Looking at the shareholder registry, we can see that 52% of the ownership is controlled by the top 11 shareholders, meaning that no single shareholder has a majority interest in the ownership.
查看股东登记册,我们可以看到11个头寸最大的股东控制着52%的所有权,这意味着没有单个股东拥有的权益超过了多数权益。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
虽然仔细研究公司的机构持股数据是有意义的,但研究分析师对该股票的看法也是有意义的。有相当数量的分析师在跟踪该股票,因此了解他们对于未来发展的总体看法可能会有所帮助。
Insider Ownership Of Immunome
Immunome的内部所有权
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
虽然“内部人士”的明确定义具有主观性,但几乎所有人都认为董事会成员是内部人士。公司管理业务,但首席执行官即使是董事会成员,也要向董事会负责。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常认为内部人士持股是一件好事。但是,在某些情况下,它会使其他股东更难以对董事会的决定进行问责。
We can report that insiders do own shares in Immunome, Inc.. As individuals, the insiders collectively own US$35m worth of the US$798m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.
我们可以报告说内部人员拥有Immunome,Inc.的股票。作为个人,内部人员集体拥有价值3500万美元的公司79800万美元。这至少表明了一些一致性。你可以点击这里查看那些内部人员是否一直在买卖。
General Public Ownership
一般大众所有权
The general public, who are usually individual investors, hold a 19% stake in Immunome. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
普通公众,通常是个人投资者,持有Immunome的19%的股份。虽然这个群体不能决定一切,但它肯定对公司的经营产生了实质性的影响。
Private Company Ownership
私有公司的所有权
We can see that Private Companies own 9.5%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
我们可以看到,私人公司拥有已发行股份的9.5%。私人公司可能是相关方。有时候内部人员通过持有私人公司的股份,而不是以个人的身份,表现出他们对一家公众公司的兴趣。虽然很难得出任何广泛的结论,但这值得注意作为进一步研究的领域。
Next Steps:
下一步:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Immunome (at least 1 which is significant) , and understanding them should be part of your investment process.
虽然考虑拥有一家公司的不同集团很值得,但更重要的是其他因素。例如,不断存在的投资风险威胁。我们已经确定Immunome存在两个警告信号(至少有一个是重要的),了解它们应该成为你的投资过程的一部分。
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
最终,未来最重要。您可以在这份关于该公司分析师预测的免费报告中获取有关信息。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?对内容感到担忧?请直接与我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?对内容感到担忧?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。